Ascletis Pharma to Present Promising Obesity Treatments at ADA Scientific Sessions

The latest update is out from Ascletis Pharma, Inc. ( (HK:1672) ).

Ascletis Pharma Inc. announced that it will present poster presentations on its investigational drugs, ASC30 and ASC47, at the 85th Scientific Sessions of the American Diabetes Association in Chicago. ASC30 is a GLP-1R biased small molecule agonist with both oral and subcutaneous administration capabilities, protected by patents until 2044. ASC47 is a muscle-preserving weight loss drug candidate, currently in Phase I trials in combination with semaglutide, showing promising results in preclinical models. These developments highlight Ascletis’s commitment to advancing obesity treatment options, potentially strengthening its position in the pharmaceutical market.

The most recent analyst rating on (HK:1672) stock is a Hold with a HK$3.94 price target. To see the full list of analyst forecasts on Ascletis Pharma, Inc. stock, see the HK:1672 Stock Forecast page.

More about Ascletis Pharma, Inc.

Ascletis Pharma Inc., incorporated in the Cayman Islands, operates in the pharmaceutical industry, focusing on the development of innovative drugs. The company specializes in creating small molecule agonists for oral and subcutaneous administration, with a market focus on obesity and related metabolic disorders.

Average Trading Volume: 6,170,529

Technical Sentiment Signal: Buy

Current Market Cap: HK$7.42B

For detailed information about 1672 stock, go to TipRanks’ Stock Analysis page.